Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KMDA Kamada	$6.47 -2.0%	$6.65	$4.74 ▼ $9.16	$371.90M	1.07	86,136 shs	42,480 shs
ORKA Oruka Therapeutics	$10.44 -0.1%	$10.01	$5.49 ▼ $31.13	$390.88M	0.47	235,756 shs	115,245 shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.30 ▼ $6.65	$381.02M	0.9	3.25 million shs	N/A
ZURA Zura Bio	$1.54 +10.8%	$1.27	$0.97 ▼ $6.35	$105.30M	0.08	387,348 shs	840,526 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KMDA Kamada	-1.97%	-1.67%	-2.12%	-3.58%	+23.95%
ORKA Oruka Therapeutics	-0.10%	-1.76%	+1.75%	-17.60%	+1,043,999,900.00%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	+0.55%	+1.11%
ZURA Zura Bio	+10.79%	+6.94%	+19.38%	-12.50%	-63.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KMDA Kamada	3.8825 of 5 stars	3.5	5.0	0.0	2.3	1.7	2.5
ORKA Oruka Therapeutics	3.1746 of 5 stars	3.6	0.0	0.0	2.9	4.2	0.6
RVNC Revance Therapeutics	2.0952 of 5 stars	3.1	0.0	4.7	0.6	1.7	0.6
ZURA Zura Bio	3.1234 of 5 stars	3.6	3.0	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KMDA Kamada	3.00	Buy	$14.67	126.69% Upside
ORKA Oruka Therapeutics	3.22	Buy	$39.86	281.77% Upside
RVNC Revance Therapeutics	2.11	Hold	$8.39	129.75% Upside
ZURA Zura Bio	3.13	Buy	$14.67	852.38% Upside

Current Analyst Ratings Breakdown

Latest ZURA, ORKA, KMDA, and RVNC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/21/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/7/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
3/6/2025	KMDA Kamada	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
2/7/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
2/4/2025	ORKA Oruka Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
2/3/2025	ORKA Oruka Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KMDA Kamada	$160.95M	2.31	$0.36 per share	17.90	$4.25 per share	1.52
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KMDA Kamada	$8.28M	$0.26	23.11	20.22	0.97	9.92%	6.30%	4.49%	5/6/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$5.79	N/A	N/A	N/A	N/A	-24.96%	-21.22%	5/1/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	5/7/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.53	N/A	N/A	N/A	N/A	-37.36%	-29.81%	5/8/2025 (Estimated)

Latest ZURA, ORKA, KMDA, and RVNC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	N/A	N/A	N/A	$154.06 million	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	N/A	N/A	N/A	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
3/6/2025	Q4 2024	ORKA Oruka Therapeutics	-$0.68	-$0.49	+$0.19	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Latest ZURA, ORKA, KMDA, and RVNC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/5/2025	KMDA Kamada	--	$0.20		3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KMDA Kamada	N/A	4.84	2.73
ORKA Oruka Therapeutics	N/A	22.89	22.89
RVNC Revance Therapeutics	N/A	4.12	3.05
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KMDA Kamada	20.38%
ORKA Oruka Therapeutics	56.44%
RVNC Revance Therapeutics	97.70%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
KMDA Kamada	36.10%
ORKA Oruka Therapeutics	22.67%
RVNC Revance Therapeutics	5.10%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KMDA Kamada	360	57.48 million	36.73 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

ZURA, ORKA, KMDA, and RVNC Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

April 30 at 5:37 AM | marketbeat.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

JPMorgan Chase & Co. Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

April 20, 2025 | marketbeat.com

ADAR1 Capital Management LLC Cuts Stake in Zura Bio Limited (NASDAQ:ZURA)

April 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings

April 8, 2025 | marketbeat.com

HC Wainwright Cuts Zura Bio (NASDAQ:ZURA) Price Target to $3.00

April 5, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

April 5, 2025 | marketbeat.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

Zura Bio Limited (NASDAQ:ZURA) Director Sells $2,734,458.09 in Stock

November 28, 2024 | insidertrades.com

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

November 25, 2024 | businesswire.com

Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab

November 15, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, ORKA, KMDA, and RVNC Company Descriptions

Kamada NASDAQ:KMDA

$6.47 -0.13 (-1.97%)

As of 04/30/2025 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Oruka Therapeutics NASDAQ:ORKA

$10.44 -0.01 (-0.10%)

As of 04/30/2025 04:00 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Zura Bio NASDAQ:ZURA

$1.54 +0.15 (+10.79%)

As of 04/30/2025 04:00 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time